NEWS legal form changed ByOncoscience 22. August 201717. July 2025 We are now Oncoscience GmbH. Managing directors are Dr. Dirk Reuter, Dr. Budhi Simon and Robert Ellerson. Ähnliche Beiträge
NEWS Oncoscience AG presents results from Phase III study of Nimotuzumab (Theraloc®) in patients with diffuse intrinsic pontine glioma at the 41. SIOP, Sao Paulo, Brazil, October 6th-9th, 2009 ByOncoscience 9. October 200917. July 2025
NEWS Oncoscience AG and GenIlac agree on cooperation terms in Turkey ByOncoscience 7. July 201017. July 2025
NEWS Publication shows benefit in patients with locally advanced or metastatic pancreatic cancer treated with nimotuzumab in combination with gemcitabine. ByOncoscience 17. November 201717. July 2025
NEWS Oncoscience AG announces final results of a phase-II study in pediatric patients with recurrent high-grade malignant glioma treated with the monoclonal antibody NIMOTUZUMAB directed against EGF-R, as monotherapy ByOncoscience 8. June 200717. July 2025
NEWS Mawdsleys and Oncoscience launch a Named Patient Program for CIMAher® (Nimotuzumab) in the U.K. and Ireland ByOncoscience 3. October 201817. July 2025
